The RegenMed Development Organization (ReMDO) is a non-profit organization that manages a consortium of more than 60 industry and academic members to advance regenerative medicine manufacturing technologies.
In partnership with the US Army Medical Research & Materiel Command (USAMRMC), the Medical Technology Enterprise Consortium (MTEC) awarded ReMDO a five million, five-year programme to develop universal bioink with tunable mechanical properties for regenerative manufacturing of clinical products.
Biogelx joined the ReMDO Advanced Biomanufacturing Initiative in 2017 and have been collaborating with other consortium members, such as Wake Forest Institute for Regenerative Medicine (WFIRM), to achieve the overall objective of this program. The aim is to formulate a base bioink with a modular cocktail of cross-linkers that can be used to tune the mechanical properties of the hydrogel, both for bioprinting, and for adjusting the final stiffness of the bioprinted construct to match the stiffness of native tissues, ensuring optimal cell survival and tissue construct function.
Biogelx specializes in tunable peptide hydrogels and bioinks that can be configured to mimic specific tissue types, and are compatible with a range of 3D printing technology.
For further information please see https://lnkd.in/gsWspS9